Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsUsing an immunocompetent mouse model expressing a humanized CD3ε chain and bispecific T cell engager (BiTE) molecules directed against mouse CD19, mouse CLDN18.2, or human EPCAM antigens, researchers investigated the pharmacokinetic and pharmacodynamic parameters and immune correlates associated with BiTE efficacy across multiple syngeneic solid-tumor models.
[Science Translational Medicine]
6445212 ERNHWGNL items 1 apa 0 default asc 1 166121 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-c8ed14565ff731849f8e01ff1d922ec9%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22ERNHWGNL%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Belmontes%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBelmontes%2C%20B.%2C%20Sawant%2C%20D.%20V.%2C%20Zhong%2C%20W.%2C%20Tan%2C%20H.%2C%20Kaul%2C%20A.%2C%20Aeffner%2C%20F.%2C%20O%26%23x2019%3BBrien%2C%20S.%20A.%2C%20Chun%2C%20M.%2C%20Noubade%2C%20R.%2C%20Eng%2C%20J.%2C%20Ma%2C%20H.%2C%20Muenz%2C%20M.%2C%20Li%2C%20P.%2C%20Alba%2C%20B.%20M.%2C%20Thomas%2C%20M.%2C%20Cook%2C%20K.%2C%20Wang%2C%20X.%2C%20DeVoss%2C%20J.%2C%20Egen%2C%20J.%20G.%2C%20%26amp%3B%20Nolan-Stevaux%2C%20O.%20%282021%29.%20Immunotherapy%20combinations%20overcome%20resistance%20to%20bispecific%20T%20cell%20engager%20treatment%20in%20T%20cell%26%23x2013%3Bcold%20solid%20tumors.%20%3Ci%3EScience%20Translational%20Medicine%3C%5C%2Fi%3E%2C%20%3Ci%3E13%3C%5C%2Fi%3E%28608%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.abd1524%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.abd1524%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DERNHWGNL%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Immunotherapy%20combinations%20overcome%20resistance%20to%20bispecific%20T%20cell%20engager%20treatment%20in%20T%20cell%5Cu2013cold%20solid%20tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Belmontes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepali%20V.%22%2C%22lastName%22%3A%22Sawant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wendy%22%2C%22lastName%22%3A%22Zhong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hong%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anupurna%22%2C%22lastName%22%3A%22Kaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Famke%22%2C%22lastName%22%3A%22Aeffner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20A.%22%2C%22lastName%22%3A%22O%5Cu2019Brien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Chun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rajkumar%22%2C%22lastName%22%3A%22Noubade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%22%2C%22lastName%22%3A%22Eng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hayley%22%2C%22lastName%22%3A%22Ma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Markus%22%2C%22lastName%22%3A%22Muenz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peng%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%20M.%22%2C%22lastName%22%3A%22Alba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Cook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoting%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%22%2C%22lastName%22%3A%22DeVoss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jackson%20G.%22%2C%22lastName%22%3A%22Egen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Nolan-Stevaux%22%7D%5D%2C%22abstractNote%22%3A%22Taking%20a%20BiTE%20out%20of%20tumors%5CnBispecific%20T%20cell%20engagers%20%28BiTE%29%20and%20other%20forms%20of%20T%20cell%20engager%20therapies%20represent%20a%20promising%20off-the-shelf%20treatment%20for%20many%20types%20of%20cancer.%20However%2C%20it%20is%20unclear%20why%20some%20types%20of%20tumors%20are%20particularly%20resistant%20to%20BiTE%20treatment.%20To%20address%20this%2C%20Belmontes%20et%20al.%20evaluated%20pharmacokinetics%2C%20pharmacodynamics%2C%20and%20immune%20correlates%20of%20responsiveness%20to%20BiTE%20treatment.%20The%20authors%20found%20that%2C%20in%20multiple%20mouse%20tumor%20models%2C%20pretreatment%20T%20cell%20density%20in%20tumors%20associated%20with%20BiTE%20efficacy.%20Further%2C%20in%20T%20cell%5Cu2013cold%20tumors%2C%20which%20lack%20abundant%20T%20cells%2C%20coadministration%20of%20immune%20checkpoint%20blockade%20antibodies%20or%20a%204-1BB%20agonist%20overcame%20resistance%20to%20BiTE%20treatment.%20Together%2C%20these%20findings%20identify%20combination%20therapeutic%20strategies%20for%20BiTE%20and%20other%20T%20cell%20engagers.%5CnTherapeutic%20approaches%20are%20needed%20to%20promote%20T%20cell%5Cu2013mediated%20destruction%20of%20poorly%20immunogenic%2C%20%5Cu201ccold%5Cu201d%20tumors%20typically%20associated%20with%20minimal%20response%20to%20immune%20checkpoint%20blockade%20%28ICB%29%20therapy.%20Bispecific%20T%20cell%20engager%20%28BiTE%29%20molecules%20induce%20redirected%20lysis%20of%20cancer%20cells%20by%20polyclonal%20T%20cells%20and%20have%20demonstrated%20promising%20clinical%20activity%20against%20solid%20tumors%20in%20some%20patients.%20However%2C%20little%20is%20understood%20about%20the%20key%20factors%20that%20govern%20clinical%20responses%20to%20these%20therapies.%20Using%20an%20immunocompetent%20mouse%20model%20expressing%20a%20humanized%20CD3%5Cu03b5%20chain%20%28huCD3e%20mice%29%20and%20BiTE%20molecules%20directed%20against%20mouse%20CD19%2C%20mouse%20CLDN18.2%2C%20or%20human%20EPCAM%20antigens%2C%20we%20investigated%20the%20pharmacokinetic%20and%20pharmacodynamic%20parameters%20and%20immune%20correlates%20associated%20with%20BiTE%20efficacy%20across%20multiple%20syngeneic%20solid-tumor%20models.%20These%20studies%20demonstrated%20that%20pretreatment%20tumor-associated%20T%20cell%20density%20is%20a%20critical%20determinant%20of%20response%20to%20BiTE%20therapy%2C%20identified%20CD8%2B%20T%20cells%20as%20important%20targets%20and%20mediators%20of%20BiTE%20activity%2C%20and%20revealed%20an%20antagonistic%20role%20for%20CD4%2B%20T%20cells%20in%20BiTE%20efficacy.%20We%20also%20identified%20therapeutic%20combinations%2C%20including%20ICB%20and%204-1BB%20agonism%2C%20that%20synergized%20with%20BiTE%20treatment%20in%20poorly%20T%20cell%5Cu2013infiltrated%2C%20immunotherapy-refractory%20tumors.%20In%20these%20models%2C%20BiTE%20efficacy%20was%20dependent%20on%20local%20expansion%20of%20tumor-associated%20CD8%2B%20T%20cells%2C%20rather%20than%20their%20recruitment%20from%20circulation.%20Our%20findings%20highlight%20the%20relative%20contributions%20of%20baseline%20T%20cell%20infiltration%2C%20local%20T%20cell%20proliferation%2C%20and%20peripheral%20T%20cell%20trafficking%20for%20BiTE%20molecule%5Cu2013mediated%20efficacy%2C%20identify%20combination%20strategies%20capable%20of%20overcoming%20resistance%20to%20BiTE%20therapy%2C%20and%20have%20clinical%20relevance%20for%20the%20development%20of%20BiTE%20and%20other%20T%20cell%20engager%20therapies.%5CnImmune%20checkpoint%20blockade%20and%204-1BB%20agonism%20overcome%20primary%20resistance%20to%20bispecific%20T%20cell%20engager%20therapy%20in%20T%20cell%5Cu2013cold%20solid%20tumors.%5CnImmune%20checkpoint%20blockade%20and%204-1BB%20agonism%20overcome%20primary%20resistance%20to%20bispecific%20T%20cell%20engager%20therapy%20in%20T%20cell%5Cu2013cold%20solid%20tumors.%22%2C%22date%22%3A%222021%5C%2F08%5C%2F25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1126%5C%2Fscitranslmed.abd1524%22%2C%22ISSN%22%3A%221946-6234%2C%201946-6242%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fstm.sciencemag.org%5C%2Fcontent%5C%2F13%5C%2F608%5C%2Feabd1524%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-08-26T16%3A12%3A41Z%22%7D%7D%5D%7D
Belmontes, B., Sawant, D. V., Zhong, W., Tan, H., Kaul, A., Aeffner, F., O’Brien, S. A., Chun, M., Noubade, R., Eng, J., Ma, H., Muenz, M., Li, P., Alba, B. M., Thomas, M., Cook, K., Wang, X., DeVoss, J., Egen, J. G., & Nolan-Stevaux, O. (2021). Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors. Science Translational Medicine, 13(608). https://doi.org/10.1126/scitranslmed.abd1524 Cite
